3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
4
Genitourinary
3
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Endocrine
2
CNS
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Dermatologic
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Fluorodeoxyglucose F18
2
tivozanib
1
tislelizumab
1
surufatinib
1
romidepsin
1
repotrectinib
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
atezolizumab
1
alectinib
1
Quality of Life
1
Patient Reported Outcome Measures
1
PM 01183
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Lactones
1
Irinotecan
1
Interleukin-2
1
Immunotherapy
1
FAPI-46
1
Drug Therapy
1
Depsipeptides
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
entrectinib
×
NET
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA